Table 2.
Univariate and multivariate analyses for overall survival in the entire cohort
| Variable | Univariate analysis |
Multivariate analysis |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | aHR | 95% CI | P-value | |
| Treatment | ||||||
| LR | 1 | Reference | - | 1 | Reference | - |
| TACE | 2.60 | 1.59-4.28 | <0.001 | 1.81 | 1.08-3.04 | 0.03 |
| Age, per 1-year increase | 1.05 | 1.03-1.07 | <0.001 | 1.06 | 1.03-1.08 | <0.001 |
| Male | 1.09 | 0.67-1.77 | 0.7 | - | - | - |
| Body mass index (kg/m2) | 0.97 | 0.92-1.03 | 0.3 | - | - | - |
| Etiology | ||||||
| Hepatitis B | 1 | Reference | - | 1 | Reference | - |
| Hepatitis C | 2.43 | 1.52-3.89 | <0.001 | 2.12 | 1.29-3.48 | 0.003 |
| Alcohol | 1.36 | 0.81-2.28 | 0.20 | 1.02 | 0.58-1.77 | >0.9 |
| Others* | 0.99 | 0.52-1.90 | 0.90 | 0.85 | 0.43-1.66 | 0.60 |
| Hypertension | 0.86 | 0.59-1.25 | 0.40 | - | - | - |
| Diabetes mellitus | 1.03 | 0.70-1.52 | 0.90 | - | - | - |
| Platelets (×1,000/mm3) | 0.99 | 0.99-1.00 | 0.03 | - | - | - |
| Ascites | - | - | - | |||
| None | 1 | Reference | - | |||
| Mild | 2.20 | 1.21-3.98 | 0.01 | |||
| Moderate to severe | 2.40 | 1.05-5.45 | 0.04 | |||
| Creatinine (mg/dL) | 0.69 | 0.27-1.77 | 0.40 | - | - | - |
| Total bilirubin (mg/dL) | 1.37 | 1.27-1.55 | <0.001 | 1.27 | 1.04-1.56 | 0.02 |
| Albumin, per 1-g/dL increase | 0.40 | 0.29-0.56 | <0.001 | - | - | - |
| PT (INR) | 28.4 | 8.0-101.0 | <0.001 | 16.8 | 2.56-110 | 0.003 |
| ALT (IU/L) | 1.00 | 1.00-1.01 | 0.10 | - | - | - |
| AFP | - | - | - | |||
| AFP <20 ng/mL | 1 | Reference | - | |||
| AFP ≥20 ng/mL | 1.15 | 0.83-1.61 | 0.40 | |||
| Number of tumors | ||||||
| 2 | 1 | Reference | - | 1 | Reference | - |
| 3 | 1.40 | 0.99-2.00 | 0.06 | 1.25 | 0.88-1.79 | 0.20 |
| Size of tumor, per 1-cm increase | 1.42 | 1.10-1.85 | 0.01 | 1.43 | 1.10-1.86 | 0.01 |
HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; LR, liver resection; TACE, transarterial chemoembolization; PT, prothrombin time; INR, international normalized ratio; ALT, alanine aminotransferase; AFP, alpha-fetoprotein.
*
Others included autoimmune hepatitis and non-alcoholic fatty liver disease.